The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 18, 2020

Filed:

Mar. 27, 2018
Applicant:

Unity Biotechnology, Inc., Brisbane, CA (US);

Inventor:

Shayne Squires, Cedarburg, WI (US);

Assignee:

Unity Biotechnology, Inc., South San Francisco, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/50 (2006.01); A61K 51/10 (2006.01); A61K 49/00 (2006.01); C07K 14/00 (2006.01); A61K 38/10 (2006.01); A61K 51/08 (2006.01); G01N 33/574 (2006.01); A61K 47/64 (2017.01); A61K 47/68 (2017.01); A61K 35/12 (2015.01); C07K 16/28 (2006.01); A61K 38/16 (2006.01); C12N 15/10 (2006.01); C12N 15/86 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/00 (2013.01); A61K 35/12 (2013.01); A61K 38/10 (2013.01); A61K 38/16 (2013.01); A61K 38/168 (2013.01); A61K 47/64 (2017.08); A61K 47/6803 (2017.08); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61K 49/0004 (2013.01); A61K 49/0056 (2013.01); A61K 51/08 (2013.01); A61K 51/088 (2013.01); A61K 51/1027 (2013.01); C07K 16/28 (2013.01); C12N 15/1037 (2013.01); C12N 15/86 (2013.01); G01N 33/5005 (2013.01); G01N 33/5032 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C12N 2710/10043 (2013.01); G01N 2800/50 (2013.01);
Abstract

Disclosed are agents (e.g., peptides, polypeptides, proteins, small molecules, antibodies, and antibody fragments that target senescent cells) and methods of their use for imaging senescent cells in vivo and for treating or preventing cancer, age-related disease, tobacco-related disease, or other diseases and disorders related to or caused by cellular senescence in a mammal. The methods include administering one or more of the agents of the invention to a mammal, e.g., a human. The agents, which specifically bind to senescent cells, can be labeled with a radioactive label or a therapeutic label, e.g., a cytotoxic agent.


Find Patent Forward Citations

Loading…